Tag Archives: Linaclotide

← Older posts

To Cover Debts, Synergy Inks $200M Bankruptcy Sale to Bausch Health

Synergy Pharmaceuticals has spent years looking for a buyer. The developer of a struggling drug for two types of chronic constipation finally has one—now that it’s gone bankrupt. New York-based Synergy (NASDAQ SGYP) cut a deal on Wednesday to sell itself to Bausch Health, a Canadian specialty pharma company, for roughly $200 million in cash. […]

Posted in Boston blog main, Boston top stories, National blog main, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , | Comments Off on To Cover Debts, Synergy Inks $200M Bankruptcy Sale to Bausch Health

Five Takeaways from “What’s Hot in Boston Biotech”

“What’s Hot in Boston Biotech” can change with the wind. One week it might be a multi-billion dollar buyout, the next a high profile startup. Keeping up with the latest high-flying companies and issues can be tricky when you’re running an event in one of biotechnology’s epicenters. This year, before a packed house at Biogen’s […]

Posted in Boston, Boston blog main, National blog main, National top stories, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Five Takeaways from “What’s Hot in Boston Biotech”

Synergy Hits Mark on Second Trial, Eyes Approval For Constipation Drug

It looks like Synergy Pharmaceuticals may have a drug on its hands. Shares of the New York-based company surged over 15 percent in pre-market trading this morning after its drug for chronic idiopathic constipation (CIC), plecanatide, hit all of its goals in the second of two Phase 3 trials. As with an earlier study in […]

Posted in Boston blog main, Boston top stories, National blog main, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , | Comments Off on Synergy Hits Mark on Second Trial, Eyes Approval For Constipation Drug

East Coast Biotech Roundup: Emulate, Pulmatrix, Synergy & More

My West Coast counterpart is crowing this week about an NBA championship for his beloved Golden State Warriors, who ended a 40-year title drought this week by toppling LeBron James and the Cleveland Cavaliers. Meanwhile, the dry spell continues for my sorry New York Knicks, who last hoisted the Larry O’Brien trophy when current president […]

Posted in Boston blog main, Boston top stories, National blog main, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Emulate, Pulmatrix, Synergy & More

East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More

After a one-week hiatus, the roundup is back, and we’ve got plenty of news to take your mind off of Ebola, the plunging stock market, and the now-defunct AbbVie-Shire megamerger. Let’s get right to it: —A month after leaving Epizyme for a return to the venture capital world, Jason Rhodes took the helm of a […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More

East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More

(Updated, 9:05 am ET) The East Coast got buried in snow this week—again—but biotech activity was raging regardless. More IPOs priced (of course). A new high-profile startup emerged from stealth. A small acquisition wowed Wall Street. Those headlines and more below: —Third Rock Ventures has had success so far with its first gene therapy portfolio […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More

East Coast Biotech Roundup: Enanta, NY Disruptors, Repligen, & More

Perhaps expectedly, it was a slow week for East Coast biotech as many took a deep breath following the JP Morgan madness. But if the crowding IPO queue is any indication, things are about to heat up in the coming weeks. In the meantime, here’s a roundup of all the local headlines, including some Xconomy […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Enanta, NY Disruptors, Repligen, & More

East Coast Life Sciences Roundup: Sarepta, Agios, Gerngross, & (Much) More

It was earnings week for a few of the big biotech staples on the East Coast, but that was far from all that happened. In case you’ve been stuck under a rock, we’ve got the highlights, lowlights, and everything in-between wrapped up below. —Cambridge, MA-based Sarepta Therapeutics (NASDAQ: SRPT) plans to submit a new drug […]

Posted in Boston, Boston blog main, National blog main, New York blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Life Sciences Roundup: Sarepta, Agios, Gerngross, & (Much) More

Ironwood, NPS Pharma Tap Wall Street To Roll Out Lead Drugs

Ironwood Pharmaceuticals and NPS Pharmaceuticals have plenty in common: both won FDA approval of their first drugs in 2012, and both are trying to prove to investors that they can successfully sell them. And now, both have sought out Wall Street to help them get it done. Cambridge, MA-based Ironwood and Bedminster, NJ-based NPS both […]

Posted in Boston, Boston blog main, National blog main, New York blog main | Tagged , , , , , , , , , , , , | Comments Off on Ironwood, NPS Pharma Tap Wall Street To Roll Out Lead Drugs

Ironwood Pharmaceuticals Wins FDA Approval For Constipation Drug

[Updated 3:23 pm ET] Ironwood Pharmaceuticals CEO Peter Hecht is fond of saying he wants to build the next great pharmaceutical company, and now he’ll have a chance to prove it. The company was cleared today by the FDA to start selling its first drug in the U.S. Cambridge, MA-based Ironwood (NASDAQ: IRWD) was given […]

Posted in Boston, Boston blog main, National blog main, National top stories | Tagged , , , , , , , , , , | 1 Comment← Older posts